Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02966782 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT02966782 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 70 participants.
The verdict
NCT02966782, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a Phase 1b, open-label, multicenter study designed to evaluate the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in participants with relapsed/refractory Myelodysplastic Syndromes (MDS).
Interventions
- DRUG venetoclax
- DRUG azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2017-03-07 |
| Est. Completion | 2023-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02966782
The ClinicalTrials.gov registry entry for NCT02966782 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which venetoclax is the first listed.
NCT02966782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02966782 about?
NCT02966782 is a clinical study titled "A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)". This is a Phase 1b, open-label, multicenter study designed to evaluate the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in participants with relapsed/refractory Myelodysplastic Syndromes (MDS).
What is the current status of trial NCT02966782?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2017-03-07. Estimated completion is 2023-04-05.
What interventions are being tested in trial NCT02966782?
The interventions under investigation include: venetoclax (DRUG), azacitidine (DRUG).
Who is sponsoring clinical trial NCT02966782?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.